ISM-6331
- Generic Name
- ISM-6331
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Phase 1
Recruiting
- Conditions
- Metastatic Malignant Solid TumorMalignant MesotheliomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 82
- Registration Number
- NCT06566079
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath